Real-World Evidence Submissions to the Center for Drug Evaluation and Research

Why It Matters

The surge demonstrates FDA’s expanding acceptance of RWE, enabling sponsors to accelerate approvals and satisfy post‑marketing commitments with real‑world data, reshaping drug development economics.

Key Takeaways

• CDER protocols with RWE rose from 10 in FY23 to 31 FY25.
• NDA/BLA submissions containing RWE increased tenfold by FY25.
• Four 2025 drug approvals credited RWE as a decision factor.
• Safety‑focused RWE protocols dominate, comprising about 70% of submissions.
• Electronic health records remain the top data source across all years.

Pulse Analysis

Under PDUFA VII, the FDA committed to publishing aggregate data on real‑world evidence submissions, a move that brings unprecedented transparency to the drug‑approval pipeline. The latest tables show a three‑fold increase in protocol submissions that embed electronic health records, claims, and registry data, signaling that sponsors are increasingly leveraging existing patient streams to answer safety and effectiveness questions. This shift aligns with the agency’s broader goal of modernizing evidentiary standards while reducing reliance on costly, traditional trials.

The numbers tell a clear story: safety‑oriented RWE studies now account for roughly 70% of all protocol submissions, reflecting regulators’ focus on post‑marketing risk mitigation. Electronic health records top the data‑source list, but registries and other sources are gaining traction, especially in the FY 2025 surge. Moreover, the rise in final study reports satisfying PMRs/PMCs indicates that RWE is becoming a routine tool for meeting FDA‑mandated commitments, potentially shortening the time to market for new indications.

For pharmaceutical companies, the trend translates into strategic imperatives. Embedding RWE early in development can streamline NDA or BLA dossiers, as evidenced by four 2025 approvals that explicitly referenced real‑world data. Companies that invest in robust data‑capture infrastructure and analytics will be better positioned to negotiate label expansions, dose adjustments, and even first‑time approvals. As the FDA continues to refine its guidance, the integration of RWE is set to become a cornerstone of efficient, evidence‑based drug development.